(GMAB) Genmab A/S SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(GMAB) Genmab A/S Complete Analysis Pack
Dive Deeper Into the Research Trail Behind the Analysis
This Genmab A/S SWOT Analysis gives a concise, company-specific breakdown of strengths, weaknesses, opportunities, and threats to support research, strategy, or investment decisions; the page already includes a real preview of the report so you can judge style and substance before buying—purchase the full version to download the complete ready-to-use analysis.
Strengths
5 commercialized products across oncology and immune diseases
Genmab has five commercial products in market use: DARZALEX, teprotumumab, ofatumumab, amivantamab, and tisotumab vedotin. That gives it a broader base than a single-asset biotech, with DARZALEX still the key revenue engine and multiple partnered launches in oncology and immune disease. This mix supports recurring cash flow and lowers product-specific risk.
About 20 active pre-clinical programs
Genmab A/S reports about 20 active pre-clinical programs, which shows a wide discovery engine and a steady pipeline behind its marketed drugs. That matters because Genmab A/S ended 2025 with DKK 25.4 billion in revenue and DKK 9.7 billion in net profit, so the base business is strong enough to fund early R&D. A deeper pre-clinical pool also helps Genmab A/S keep long-term growth alive as current products mature.
Deep focus on antibody therapies
Founded in 1999, Genmab A/S is built around antibody discovery and development, so its core know-how sits in a high-value drug class. Its pipeline spans human monoclonal antibodies, bispecific antibodies, and other engineered formats, which sharpens focus and speeds repeatable R&D execution. This specialization matters because antibody drugs are a major growth area in oncology and immunology.
Broad late-stage pipeline across cancer and rare disease
Genmab A/S has a broad late-stage pipeline in oncology and rare disease, led by GEN1047, epcoritamab, HexaBody-CD38, DuoHexaBody-CD37, and multiple Phase 2 programs. That mix spans celiac disease, hemophilia A, and multiple system atrophy, so it lifts the odds of several future approvals.
- Late-stage depth across cancer and rare disease
- Multiple shots at approval from Phase 2 assets
- Broader mix lowers single-program risk
8 strategic collaborators named in the business model
Genmab's business model lists 8 strategic collaborators: Seagen, CureVac, AbbVie, BioNTech, Janssen, Novo Nordisk, BliNK Biomedical SAS, and Bolt Biotherapeutics. This partner network widens research access and speeds development across multiple programs. It also spreads technical and financial risk, so no single company carries the full burden.
- 8 named partners strengthen reach
- Broader R&D capacity
- Shared cost and risk
Genmab’s Strong 2025 Profit and Pipeline Reduce Risk
Genmab A/S ended 2025 with DKK 25.4 billion in revenue and DKK 9.7 billion in net profit, which gives it strong internal funding for R&D. Its five marketed products and about 20 pre-clinical programs reduce single-asset risk and support long-term growth. A broad partner base also shares cost, speed, and technical risk.
| Strength | 2025 data |
|---|---|
| Revenue | DKK 25.4bn |
| Net profit | DKK 9.7bn |
| Marketed products | 5 |
| Pre-clinical programs | About 20 |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Genmab A/S’s business strategy
Editable Excel File
Gives a clear, concise SWOT view of Genmab A/S to speed strategic decisions and stakeholder alignment.
Reference Sources
Lists primary, reputable sources (clinical data, financial filings, industry reports) to speed due diligence and let investors verify Genmab assumptions quickly.
Weaknesses
Only 5 commercial products
Genmab’s marketed portfolio still has only 5 commercial products, so revenue is concentrated and each asset matters more. That makes the company more exposed to any slowdown, pricing pressure, or trial miss in one product. DARZALEX remains the key driver, so even one product’s swing can still move overall momentum materially.
Partnered economics on key assets
Genmab A/S depends on shared control for key assets like tisotumab vedotin with Seagen and epcoritamab with AbbVie, so it does not keep all product economics. That cuts gross upside and can slow decisions on pricing, label expansion, and launch timing. This matters more as partner-led programs drive a larger share of Genmab A/S value, but Genmab A/S still gives up part of the economics and strategic control.
Most of the pipeline is still unapproved
Most of Genmab A/S’s pipeline is still unapproved, with many programs in Phase 2 or earlier, so they are not yet adding commercial sales. That leaves near-term growth tied to existing marketed assets such as DARZALEX royalties and Tivdak, while new drugs still face clinical and regulatory risk. In 2025, Genmab’s revenue was still driven mainly by partnered and approved products, not by pipeline launches.
Heavy exposure to cancer and blood cancer markets
Genmab A/S remains heavily tied to oncology and hematology, so a few cancer markets drive most of its value. That makes results more exposed to shifts in treatment standards, trial data, and rivals in blood cancer. In 2025, its revenue mix was still led by cancer-linked products and royalties.
The risk is concentration: if one major therapy slows, the impact can be material because the portfolio is not broad across many disease areas. That leaves Genmab A/S more sensitive to pricing pressure, label changes, and new entrants in multiple myeloma and lymphoma.
- High reliance on cancer markets
- Limited therapy diversification
- Strong exposure to rival drug launches
- Higher sensitivity to standard-of-care shifts
Development complexity across many programs
Genmab A/S is juggling about 20 pre-clinical programs plus multiple clinical assets, so development work is spread across many shots at once. That breadth raises trial, CMC, and regulatory complexity, and it can stretch internal teams and cash. One weak asset can still absorb years of spend before it fails, while only a few programs need to win to justify the pipeline.
- About 20 pre-clinical programs
- Multiple clinical assets in parallel
- Higher risk of sunk R&D spend
Genmab’s Growth Is Still Tied to a Few Key Drugs
Genmab A/S still has concentrated revenue: 5 commercial products and heavy DARZALEX dependence. Partner control also limits upside on tisotumab vedotin and epcoritamab, while most pipeline assets remain pre-approval. Cancer exposure stays high, so pricing, rival launches, and standard-of-care shifts can hit fast.
| Weakness | Data |
|---|---|
| Commercial concentration | 5 products |
| Partner dependence | Key shared-control assets |
| Pipeline risk | Many Phase 2 or earlier |
| Therapy mix | Mostly oncology/hematology |
Preview the Actual Deliverable
Genmab A/S Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content is pulled straight from the final file. Buy now to unlock the complete, editable Genmab A/S analysis.
Opportunities
Label expansion for DARZALEX and other marketed assets
DARZALEX already covers multiple myeloma, some non-MM blood cancers, and AL amyloidosis, and Johnson & Johnson reported 2024 sales of about $11.7 billion for the brand. More label wins could lift patient reach and keep the franchise growing beyond its current use cases. For Genmab A/S, that would stretch the cash flow life of its core royalty asset.
Advancing Phase 2 programs into late-stage trials
Advancing Phase 2 assets into late-stage studies can add real upside for Genmab A/S, especially for programs such as Camidanlumab tesirine, PRV-015, Mim8, and Lu AF82422. Positive data can justify registration trials and turn mid-stage reads into larger value inflection points, while the approved Teclistamab also supports the company’s oncology track record. Each step forward broadens the pipeline and reduces reliance on any single program.
Growth in solid-tumor immunotherapy
GEN1047, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB all target solid tumors, which make up about 90% of adult cancers and remain a far larger market than blood cancers. If one of these programs works, Genmab A/S could add a new revenue engine and reduce reliance on hematologic oncology. That matters because the global immuno-oncology market was already worth tens of billions of dollars in 2025.
Use of partner platforms to accelerate development
Genmab A/S can use partner platforms to move faster because it already works with large biopharma groups, so it can share R&D costs and tap tools it may not own in-house. That matters in oncology, where one late-stage study can run into hundreds of millions of dollars and access to specialized antibody and data platforms can shorten timelines.
- Shares cost and risk with partners
- Accesses specialized tech faster
- Expands trial reach beyond Genmab A/S alone
These alliances can also widen global development and commercial reach, which helps Genmab A/S push more programs at once without building every capability itself.
New modality growth through mRNA and bispecific platforms
Genmab A/S can widen its growth base through the CureVac collaboration, which targets differentiated mRNA-based antibody products that go beyond standard monoclonal antibodies. Its pipeline also includes multiple DuoBody and HexaBody assets, giving it more shots at creating first- or best-in-class cancer and immune therapies. This mix can lift long-term product diversity and reduce reliance on any one antibody format.
- mRNA adds a new modality
- DuoBody and HexaBody expand reach
- More pipeline shots, less concentration
Genmab’s Next Growth Drivers Beyond DARZALEX
Genmab A/S can still grow DARZALEX royalties if Johnson & Johnson keeps expanding label use; 2024 DARZALEX sales were about $11.7 billion. New late-stage wins in Mim8, camidanlumab tesirine, and PRV-015 could also add value and cut dependence on one asset. Solid-tumor shots like GEN1047 are the biggest upside if they work.
| Opportunity | Latest data |
|---|---|
| DARZALEX | $11.7B sales in 2024 |
| Solid tumors | ~90% of adult cancers |
| Partnered R&D | Shares cost and risk |
Threats
Intense competition in oncology and hematology
Genmab A/S faces intense rivalry in multiple myeloma, NSCLC, CLL, and cervical cancer, where rivals from Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Roche keep raising the bar. In multiple myeloma alone, more than 20 approved options now crowd the field, which can cap pricing power and slow uptake for new launches. As competitors add faster, safer, or combination therapies, product lifecycles can shorten and peak sales can arrive earlier.
Clinical trial failure risk across many programs
Genmab A/S faces trial failure risk across multiple investigational and Phase 2 programs, so one weak readout can hit more than one growth driver. Any negative efficacy or safety result can delay, reshape, or end development, and mid-stage data often drives partner interest and valuation. A setback in one lead asset can quickly cut future sales expectations and pressure the stock.
Dependence on external partners
Genmab A/S still depends on partners for several key assets, so any shift in their priorities can slow studies, filing work, and launches. Darzalex sales were about US$11.7 billion in 2024, so Genmab's royalty stream is tied to Johnson & Johnson's execution and strategy. If a partner cuts spend or delays a program, timelines and future cash flow can slip fast.
Regulatory scrutiny for novel antibody therapies
Genmab A/S’s advanced antibody formats and combo regimens can draw tougher safety and benefit-risk review, especially when trials are small or endpoints are complex. Regulatory delays or extra data asks can add 6-18 months to development, raising cash burn and pushing back launch timing for assets that often need large, multi-arm studies.
- Higher FDA and EMA scrutiny
- More safety data can be required
- Delays lift R&D cost and burn
- Launch timing can slip by years
Execution risk across a broad pipeline
Genmab A/S is running commercial products, late-stage trials, Phase 2 studies, and about 20 pre-clinical programs at once, so execution risk is high. That breadth can stretch management attention and capital, and one miss can hit several assets at the same time. In a portfolio this broad, delays or trial setbacks can quickly ripple across revenue and pipeline value.
- Broad pipeline strains focus and capital allocation
- One execution slip can affect multiple programs
Genmab Faces Heavy Myeloma Competition and Darzalex Dependence
Genmab A/S faces steep rivalry, with more than 20 approved multiple myeloma options and heavy pressure from Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Roche. Darzalex sales were about US$11.7 billion in 2024, so Genmab A/S’s royalty base still hinges on partner execution. Trial failures, safety issues, and regulator delays can quickly cut value and push launches out.
| Threat | Data point |
|---|---|
| Darzalex dependence | US$11.7B sales, 2024 |
| Myeloma competition | 20+ approved options |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.